163 related articles for article (PubMed ID: 15502019)
1. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass.
Chavez JJ; Foley DE; Snider CC; Howell JC; Cohen E; Muenchen RA; Carroll RC
Anesth Analg; 2004 Nov; 99(5):1290-1294. PubMed ID: 15502019
[TBL] [Abstract][Full Text] [Related]
2. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin.
Wang JS; Lin CY; Hung WT; Karp RB
Anesthesiology; 1992 Dec; 77(6):1080-4. PubMed ID: 1281624
[TBL] [Abstract][Full Text] [Related]
4. Impact of protamine dose on activated clotting time and thromboelastography in infants and small children undergoing cardiopulmonary bypass.
Gautam NK; Schmitz ML; Harrison D; Zabala LM; Killebrew P; Belcher RH; Prodhan P; McKamie W; Norvell DC
Paediatr Anaesth; 2013 Mar; 23(3):233-41. PubMed ID: 23279140
[TBL] [Abstract][Full Text] [Related]
5. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
[TBL] [Abstract][Full Text] [Related]
6. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.
Koster A; Despotis G; Gruendel M; Fischer T; Praus M; Kuppe H; Levy JH
Anesth Analg; 2002 Jul; 95(1):26-30, table of contents. PubMed ID: 12088937
[TBL] [Abstract][Full Text] [Related]
7. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability.
Dirkmann D; Nagy E; Britten MW; Peters J
BMC Anesthesiol; 2019 Sep; 19(1):174. PubMed ID: 31492108
[TBL] [Abstract][Full Text] [Related]
8. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays.
Murray DJ; Brosnahan WJ; Pennell B; Kapalanski D; Weiler JM; Olson J
J Cardiothorac Vasc Anesth; 1997 Feb; 11(1):24-8. PubMed ID: 9058215
[TBL] [Abstract][Full Text] [Related]
9. Heparinase thromboelastography compared with activated coagulation time for protamine titration after cardiopulmonary bypass.
Levin AI; Heine AM; Coetzee JF; Coetzee A
J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):224-9. PubMed ID: 24461364
[TBL] [Abstract][Full Text] [Related]
10. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
11. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
[TBL] [Abstract][Full Text] [Related]
12. Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT.
Ganter MT; Dalbert S; Graves K; Klaghofer R; Zollinger A; Hofer CK
Anesth Analg; 2005 Aug; 101(2):308-314. PubMed ID: 16037133
[TBL] [Abstract][Full Text] [Related]
13. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.
Despotis GJ; Filos KS; Levine V; Alsoufiev A; Spitznagel E
Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779
[TBL] [Abstract][Full Text] [Related]
14. Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec ACT and Hemochron Jr apparatus.
Svenmarker S; Appelblad M; Jansson E; Häggmark S
Perfusion; 2004; 19(5):289-94. PubMed ID: 15506033
[TBL] [Abstract][Full Text] [Related]
15. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
[TBL] [Abstract][Full Text] [Related]
16. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph.
Khan NU; Wayne CK; Barker J; Strang T
Eur J Anaesthesiol; 2010 Jul; 27(7):624-7. PubMed ID: 20485179
[TBL] [Abstract][Full Text] [Related]
17. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses.
Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG
Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695
[TBL] [Abstract][Full Text] [Related]
18. Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution.
Lee JM; Park EY; Kim KM; Won JC; Jung TK; Lee SK
J Int Med Res; 2018 Feb; 46(2):873-882. PubMed ID: 28974132
[TBL] [Abstract][Full Text] [Related]
19. Optimal protamine dosing after cardiopulmonary bypass: The PRODOSE adaptive randomised controlled trial.
Miles LF; Burt C; Arrowsmith J; McKie MA; Villar SS; Govender P; Shaylor R; Tan Z; De Silva R; Falter F
PLoS Med; 2021 Jun; 18(6):e1003658. PubMed ID: 34097705
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the effect of kaolin and tissue-factor-activated citrated whole blood, on clot-forming variables, as evaluated by thromboelastography.
Johansson PI; Bochsen L; Andersen S; Viuff D
Transfusion; 2008 Nov; 48(11):2377-83. PubMed ID: 18657078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
